FTH Faeth Therapeutics Inc.

Price (delayed)

$32.97

Market cap

$851.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$141.65

Enterprise value

$825.65M

?
Relative Growth: Rel. Growth: 3
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 0

Sensei Biotherapeutics is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active ...

Highlights
The quick ratio has soared by 163% YoY and by 36% from the previous quarter
FTH's debt has plunged by 77% YoY and by 43% from the previous quarter
The net income has declined by 6% since the previous quarter

Key stats

What are the main financial stats of FTH

FTH stock price

How has the Faeth Therapeutics stock price performed over time
Intraday
-4.49%
1 week
-0.42%
1 month
16.54%
1 year
320.95%
YTD
209%
QTD
31.88%

Financial performance

How have Faeth Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$198.82M
Net income
-$195.53M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 7% from the previous quarter
The net income has declined by 6% since the previous quarter

Price vs fundamentals

How does FTH's price correlate with its fundamentals

Growth

What is Faeth Therapeutics's growth rate over time

Valuation

What is Faeth Therapeutics stock price valuation
P/E
N/A
P/B
0.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The price to book (P/B) is 48% lower than the 5-year quarterly average of 0.5

Efficiency

How efficient is Faeth Therapeutics business performance
The company's return on assets has shrunk by 176% YoY but it rose by 32% QoQ
The ROIC has soared by 59% QoQ

Dividends

What is FTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FTH.

Financial health

How did Faeth Therapeutics financials performed over time
The quick ratio has soared by 163% YoY and by 36% from the previous quarter
Faeth Therapeutics's current ratio has soared by 158% YoY and by 37% from the previous quarter
FTH's debt is 100% less than its equity
FTH's debt to equity has surged by 100% since the previous quarter but it has dropped by 100% year-on-year
FTH's debt has plunged by 77% YoY and by 43% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.